The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2026 | Ramantamig safety and efficacy in relapsed/refractory multiple myeloma
Jeffrey Matous, MD, discusses updated safety and efficacy data for ramantamig, a dual-targeting BCMA- and GPRC5D-directed T-cell-redirecting antibody, from the Phase I TRIlogy-1 trial (NCT05652335) in patients with relapsed/refractory (R/R) multiple myeloma. He highlights the absence of new safety signals and suggests that treatment-related adverse effects, including taste disturbances associated with GPRC5D targeting, may be less frequent than with earlier agents targeting these antigens. This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
